



Post Authorisation Assessments

Tilmicosol 250 mg/ml Solution for Use in Drinking Water/Milk Vm 32823/4003

•	07 November 2023	Introduction of a new immediate packaging container of the finished product.
•	23 December 2021	Change in the invented name of the veterinary medicinal product from Tilmic 250 mg/ml, koncentrat til oral opløsning til brug i drikkevand to Tilmicosol 250 mg/ml, koncentrat til oral opløsning til brug i drikkevand.
•	07 September 2021	Minor changes to an approved test procedure of the finished product.
•	17 March 2021	Addition of a manufacturer of the active substance.
•	06 November 2020	Change in the address of the marketing authorisation holder from Lavet Pharmaceuticals Ltd., 1161 Budapest, Ottó u. 14., Hungary to Lavet Pharmaceuticals Ltd., H-2143 Kistarcsa, Batthyány u. 6., Hungary. SPC/QRD updated following a variation procedure.
•	06 December 2018	Minor change in the manufacturing process of the finished product.
•	12 December 2017	Change in the QPPV of an existing pharmacovigilance system as described in the DDPS.
•	17 February 2016	Renewal – UK CMS
•	10 July 2015	Change in the manufacturer of the active substance.
•	15 August 2012	Change of medicinal product name in Poland only.